DK1372650T3 - Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat - Google Patents

Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat

Info

Publication number
DK1372650T3
DK1372650T3 DK02719992T DK02719992T DK1372650T3 DK 1372650 T3 DK1372650 T3 DK 1372650T3 DK 02719992 T DK02719992 T DK 02719992T DK 02719992 T DK02719992 T DK 02719992T DK 1372650 T3 DK1372650 T3 DK 1372650T3
Authority
DK
Denmark
Prior art keywords
epothilone
antidiarrheal agent
combinations containing
derivative
antidiarrheal
Prior art date
Application number
DK02719992T
Other languages
Danish (da)
English (en)
Inventor
John David Rothermel
Horst F Schran
Diane Greeley
Tianling Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1372650T3 publication Critical patent/DK1372650T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK02719992T 2001-03-19 2002-03-18 Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat DK1372650T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27715301P 2001-03-19 2001-03-19
US27720701P 2001-03-20 2001-03-20
PCT/EP2002/002977 WO2002074042A2 (en) 2001-03-19 2002-03-18 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative

Publications (1)

Publication Number Publication Date
DK1372650T3 true DK1372650T3 (da) 2009-03-16

Family

ID=26958333

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02719992T DK1372650T3 (da) 2001-03-19 2002-03-18 Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat

Country Status (26)

Country Link
US (1) US7030147B2 (cg-RX-API-DMAC7.html)
EP (1) EP1372650B1 (cg-RX-API-DMAC7.html)
JP (2) JP2004519493A (cg-RX-API-DMAC7.html)
KR (1) KR100863089B1 (cg-RX-API-DMAC7.html)
CN (1) CN100540001C (cg-RX-API-DMAC7.html)
AT (1) ATE414514T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002251067B2 (cg-RX-API-DMAC7.html)
BR (1) BR0208142A (cg-RX-API-DMAC7.html)
CA (1) CA2440111C (cg-RX-API-DMAC7.html)
CY (1) CY1108845T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ302848B6 (cg-RX-API-DMAC7.html)
DE (1) DE60229922D1 (cg-RX-API-DMAC7.html)
DK (1) DK1372650T3 (cg-RX-API-DMAC7.html)
ES (1) ES2318001T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0303621A3 (cg-RX-API-DMAC7.html)
IL (1) IL157333A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03008462A (cg-RX-API-DMAC7.html)
NO (1) NO333106B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ541703A (cg-RX-API-DMAC7.html)
PT (1) PT1372650E (cg-RX-API-DMAC7.html)
RU (1) RU2330661C2 (cg-RX-API-DMAC7.html)
SI (1) SI1372650T1 (cg-RX-API-DMAC7.html)
SK (1) SK287334B6 (cg-RX-API-DMAC7.html)
TW (1) TWI331525B (cg-RX-API-DMAC7.html)
WO (1) WO2002074042A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200306318B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU2001280120A1 (en) * 2000-08-24 2002-03-04 Chugai Seiyaku Kabushiki Kaisha Cyclic peptide derivative
ATE554756T1 (de) 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
US6727261B2 (en) * 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US20040242568A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06001601A (es) * 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
RU2253440C1 (ru) * 2004-03-31 2005-06-10 Открытое Акционерное Общество "Фаберлик" Средство для устранения нарушений нейрогенной и эндокринной регуляции системы капиллярного кровотока
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
GEP20135791B (en) * 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
NZ566799A (en) * 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
BRPI0820338A2 (pt) * 2007-11-09 2017-05-02 Novartis Ag corticosteroides para tratar a diarreia induzida por epotilona ou derivado da epotilona
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
KR101478925B1 (ko) * 2013-12-31 2015-01-08 아주대학교산학협력단 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301831D0 (sv) * 1993-05-28 1993-05-28 Analytecon S A Pharmaceutical compositions
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6103487A (en) * 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
BR9916833A (pt) * 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites

Also Published As

Publication number Publication date
CA2440111A1 (en) 2002-09-26
CN1622805A (zh) 2005-06-01
CY1108845T1 (el) 2014-07-02
RU2330661C2 (ru) 2008-08-10
MXPA03008462A (es) 2003-12-08
US7030147B2 (en) 2006-04-18
IL157333A0 (en) 2004-02-19
HUP0303621A3 (en) 2005-03-29
AU2002251067B2 (en) 2005-05-26
SK11702003A3 (sk) 2004-02-03
KR100863089B1 (ko) 2008-10-13
NO20034094D0 (no) 2003-09-15
JP2004519493A (ja) 2004-07-02
EP1372650A2 (en) 2004-01-02
SK287334B6 (sk) 2010-07-07
CZ20032529A3 (cs) 2004-09-15
US20040092478A1 (en) 2004-05-13
KR20040025907A (ko) 2004-03-26
TWI331525B (en) 2010-10-11
CN100540001C (zh) 2009-09-16
ZA200306318B (en) 2005-02-23
HUP0303621A2 (hu) 2004-03-01
SI1372650T1 (sl) 2009-04-30
NO333106B1 (no) 2013-03-04
HK1061516A1 (en) 2004-09-24
PL363427A1 (en) 2004-11-15
ES2318001T3 (es) 2009-05-01
WO2002074042A2 (en) 2002-09-26
PT1372650E (pt) 2009-02-25
BR0208142A (pt) 2004-03-02
WO2002074042A3 (en) 2003-02-27
NZ541703A (en) 2007-04-27
RU2003130058A (ru) 2005-04-10
EP1372650B1 (en) 2008-11-19
NO20034094L (no) 2003-09-15
ATE414514T1 (de) 2008-12-15
DE60229922D1 (de) 2009-01-02
JP2010006830A (ja) 2010-01-14
CA2440111C (en) 2010-12-07
CZ302848B6 (cs) 2011-12-14

Similar Documents

Publication Publication Date Title
ATE414514T1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
CY1112442T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
NO20053817D0 (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
BR0214309A (pt) Derivados aril-1,4-pirazina substituìdos
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
AU2003237367A1 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
NO20013452L (no) Benzoheterocykler og deres anvendelse som MEK-inhibitorer
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
NO20022528D0 (no) Kjemiske derivater og deres anvendelse som anti- telomerasemiddel
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
ITRM20020042U1 (it) Manico componibile perfezionato, in particolare manico per scope e simili.
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
IS6033A (is) Tálmar við amínótransferasa, sem háðir eru amínósýru með greinóttum keðjum, og notkun þeirra til meðhöndlunar á sjónusjúkdómum af völdum sykursýki
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20043173L (no) Benzotiazol- og benzoksazol-4,7-dionderivater og deres anvendelse som CDC25-fosfataseinhibitorer
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv